Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox

Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis inMdr2−/−mice

(2014) Kim R. Bridle et al.   LIVER INTERNATIONAL

Adipocyte iron regulates adiponectin and insulin sensitivity

(2012) J. Scott Gabrielsen et al.   JOURNAL OF CLINICAL INVESTIGATION

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats

(2011) Kosuke Kaji et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis

(2011) Terrence C. H. Tan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

(2011) Yves Deugnier et al.   GASTROENTEROLOGY

Efficacy of deferasirox in reducing and preventing cardiac iron overload in  -thalassemia

(2009) D. J. Pennell et al.   BLOOD

Deferasirox Reduces Iron Overload in a Murine Model of Juvenile Hemochromatosis

(2009) Hanspeter Nick et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways

(2009) Kim R. Bridle et al.   LIVER TRANSPLANTATION

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

(2008) Shahina Daar et al.   EUROPEAN JOURNAL OF HAEMATOLOGY